end-stage-kidney-disease (ESKD). The target of therapy is complete response (proteinuria $<0.5\text{--}0.7\text{g}/24\text{h}$ with [near-normal glomerular filtration rate] by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3g/day, or mycophenolic acid at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500mg x6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-term maintenance treatment with MMF or azathioprine should follow, with no or low-dose ($<7.5\text{mg}/\text{day}$) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria $>1\text{g}/24\text{h}$ despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations.

Conclusion: The updated recommendations intend to inform rheumatologists, nephrologists, patients, national professional societies, hospital officials, social security agencies and regulators about the treatment of LN based on most recent evidence.

Disclosure of Interests: Antonis Fanouriakis Paid instructor for: Paid instructor for Enorasis, Amgen, Speakers bureau: Paid speaker for Roche, Genesis Pharma, Mylan, Myrto Kostopoulou: None declared, Kim Cheema: None declared, Hans-Joachim Anders: None declared, Martin Aringer Consultant of: Boehringer Ingelheim, Roche, Speakers bureau: Boehringer Ingelheim, Roche, Ingeborg Bajema Consultant of: GSK, John N. Boletis Grant/research support from: GSK, Pfizer, Paid instructor for: GSK, Abbvie, UCB, Enorasis, Eleni Frangou: None declared, Frederic Houssiau Grant/research support from: UCB, Consultant of: GSK, Jane Hollis: None declared, Alexandre Karras: None declared, Francesca Marchiori: None declared, Stephen Marks: None declared, Gabriela Moroni: None declared, Marta Mosca: None declared, Ioannis Parodis: None declared, Manuel Praga: None declared, Matthias Schneider Grant/research support from: GSK, UCB, Abbvie, Consultant of: Abbvie, Alexion, AstraZeneca, BMS, Boehringer Ingelheim, Gilead, Lilly, Sanofi, UCB, Speakers bureau: Abbvie, AstraZeneca, BMS, Chugai, GSK, Lilly, Pfizer, Sanofi, Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Vladimir Tesar: None declared, Maria Trachana: None declared, Ronald van Vollenhoven Grant/research support from: AbbVie, Amgen, Arthrogen, Bristol-Myers Squibb, GlaxoSmithKline (GSK), Janssen Research & Development, LLC, Lilly, Pfizer, Roche, and UCB, Consultant of: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, GSK, Janssen, Lilly, Medac, Merck, Novartis, Pfizer, Roche, UCB and Vertex, Speakers bureau: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, Vertex, Alexandre Voskuyl: None declared, Y.K. Onno Teng Grant/research support from: GSK, Consultant of: GSK, Aurinia Pharmaceuticals, Novartis, Bernadette van Leeuw: None declared, George Bertis Grant/research support from: GSK, Consultant of: Novartis, David Jayne Grant/research support from: ChemoCentryx, GSK, Roche/Genentech, Sanofi-Genzyme, Consultant of: Astra-Zeneca, ChemoCentryx, GSK, InflaRx, Takeda, Insmed, Chugai, Boehringer-Ingelheim, Dimitrios Boumpas: None declared

DOI: 10.1136/annrheumdis-2020-eular.3870

OP0164

BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

R. Furie¹, B. H. Rovin², F. Houssiau³, Z. Amoura^{4,5}, M. Santiago⁶, G. Contreras⁷, A. Malvar⁸, C. C. Mok⁹, A. Saxena¹⁰, X. Yu¹¹, Y. K. O. Teng¹², C. Barnett¹³, S. Burris¹⁴, Y. Green¹⁵, B. Ji¹³, C. Kleoudis¹⁵, D. Roth¹⁴, ¹Northwell Health, Great Neck, United States of America; ²The Ohio State University, Columbus, United States of America; ³Cliniques Universitaires Saint-Luc, Brussels, Belgium; ⁴Sorbonne Université, Paris, France; ⁵Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁶Escola de Medicina e Saúde Pública, Salvador Bahia, Brazil; ⁷University of Miami Miller School of Medicine, Miami, United States of America; ⁸Organizacion Medica de

Investigacion, Buenos Aires, Argentina; ⁹Tuen Mun Hospital, Hong Kong SAR, China; ¹⁰NYU School of Medicine, New York City, United States of America; ¹¹The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; ¹²Leiden University Medical Center, Leiden, Netherlands; ¹³GlaxoSmithKline, Uxbridge, United Kingdom; ¹⁴GlaxoSmithKline, Collegeville, United States of America; ¹⁵Parexel, Durham, United States of America

Background: Lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), affects nearly 70% of patients (pts) in high-risk groups. To preserve renal function, LN requires fast and effective treatment. Despite medical advances, progression rates at 15 years to end-stage renal disease (ESRD) remain $>40\%$ for pts with diffuse proliferative LN. Belimumab (BEL), approved in pts aged ≥ 5 years with active SLE, improved renal parameters in pts with baseline renal involvement in a *post hoc* analysis of Phase 3 trials data.

Objectives: To assess efficacy and safety of intravenous (IV) BEL vs placebo (PBO), plus standard therapy (ST), in pts with active LN.

Methods: BLISS-LN is a Phase 3, randomised, double-blind, PBO-controlled, 104-week study (GSK Study BEL114054, NCT01639339). Adults with SLE and biopsy-proven LN (class III, IV, and/or V) were randomised (1:1) to monthly BEL 10mg/kg IV or PBO, plus ST. Primary endpoint: Primary Efficacy Renal Response (PERR); defined as urine protein creatinine ratio [uPCR] ≤ 0.7 ; estimated glomerular filtration rate [eGFR] within 20% of the pre-flare value or $\geq 60\text{ml}/\text{min}/1.73\text{m}^2$; no rescue therapy) at Week (Wk) 104. Key secondary endpoints: Complete Renal Response (CRR; defined as uPCR <0.5 ; eGFR within 10% of the pre-flare value or $\geq 90\text{ml}/\text{min}/1.73\text{m}^2$; no rescue therapy) at Wk 104; PERR at Wk 52; time to renal-related event (defined as ESRD/doubling of serum creatinine/renal worsening/renal disease-related treatment failure) or death. Other endpoints: time to PERR/CRR sustained through Wk 104; SLEDAI-S2K score <4 points at Wk 104; safety.

Results: Overall, 448 pts were randomised (efficacy: 223/group; safety: 224/group). Significantly more BEL (43%) than PBO (32.3%) pts achieved PERR at Wk 104 (OR 1.55, 95% CI 1.04, 2.32; $p=0.0311$). More BEL than PBO pts achieved key secondary and other efficacy endpoints (Table).

Overall, 214 (95.5%) BEL and 211 (94.2%) PBO pts had ≥ 1 adverse event (AE); 58 (25.9%) BEL and 67 (29.9%) PBO pts had ≥ 1 serious AE; 29 (12.9%) pts in each group had ≥ 1 AE resulting in study treatment discontinuation; 4 (1.8%) BEL and 3 (1.3%) PBO pts developed on-treatment fatal AEs.

Conclusion: In the largest LN study to date, data from BLISS-LN demonstrate that BEL plus ST significantly improves LN renal responses compared with ST alone with a favourable safety profile.

Study funding: GSK.

Table.

Endpoint, n (%)	PBO (n=223)	BEL (n=223)	OR/HR (95% CI) vs PBO	p-value
CRR at Wk 104*	44 (19.7)	67 (30.0)	OR 1.74 (1.11, 2.74)	0.0167
PERR at Wk 52*	79 (35.4)	104 (46.6)	OR 1.59 (1.06, 2.38)	0.0245
Time to PERR through Wk 104†	72 (32.3)	96 (43.0)	HR 1.46 (1.07, 1.98)	0.0157
Time to CRR through Wk 104†	44 (19.7)	67 (30.0)	HR 1.58 (1.08, 2.31)	0.0189
Time to renal-related event or death†	63 (28.3)	35 (15.7)	HR 0.51 (0.34, 0.77)	0.0014
SLEDAI-S2K score <4 points at Wk 104*	41 (18.4)	62 (27.8)	OR 1.76 (1.11, 2.78)	0.0164

*PBO and BEL columns represent the n (%) responders

†Data presented as n (cumulative incidence)

Disclosure of Interests: Richard Furie Grant/research support from: GSK, Consultant of: GSK, Brad H Rovin Grant/research support from: GSK, Consultant of: GSK, Frederic Houssiau Grant/research support from: UCB, Consultant of: GSK, Zahir Amoura Grant/research support from: GSK, Roche, Consultant of: GSK, AstraZeneca, Amgen, Mittermayer Santiago: None declared, Gabriel Contreras Grant/research support from: Genentech, Merck, Consultant of: Genentech, Merck, Ana Malvar Consultant of: GSK and Roche, chi chiu mok: None declared, Amit Saxena Consultant of: GSK, AZ, BMS, Xueqing Yu: None declared, Y.K. Onno Teng Grant/research support from: GSK, Consultant of: GSK, Aurinia Pharmaceuticals, Novartis, Carly Barnett Shareholder of: GSK, Employee of: GSK, Susan Burris Shareholder of: GSK, Employee of: GSK, Yulia Green Shareholder of: GSK, Employee of: GSK, Beulah Ji Shareholder of: GSK, Employee of: GSK, Christi Kleoudis Shareholder of: GSK, Consultant of: GSK, Employee of: Parexel, David Roth Shareholder of: GSK, Employee of: GSK

DOI: 10.1136/annrheumdis-2020-eular.3881